ReviewJournal of cancer research and clinical oncology2020
Signaling pathways and clinical application of RASSF1A and SHOX2 in lung cancer.
Review in Journal of cancer research and clinical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- [Diagnostic Efficacy of SHOX2 Gene Hypermethylation for Lung Cancer: A Meta-Analysis].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2021Pooled it
- Article
- Multimodal modeling based on DNA methylation analysis in bronchoalveolar lavage fluid for early lung cancer detection.Scientific reports · 2026Article
- Review
- RASSF1A and its epigenetic dysregulation in genitourinary cancer: a current update.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Transcript-Specific DNA Methylation Alterations of the RASSF1 Locus in Cancer Cells.Genes, chromosomes & cancer · 2026Article
- Shox2 and Rassf1a DNA methylation: diagnostic utility and association with clinical stage, histological progression and gene mutational landscape in lung adenocarcinoma.Frontiers in oncology · 2026Article
- Noninvasive early diagnosis of laryngeal squamous cell carcinoma (LSCC) revealing the high-performance potential of the HOXD10 gene monomethylated locus: a case-control study.Clinical epigenetics · 2025Article
- Review
- Exploring the prognostic role and expression patterns of FAM3A family genes in kidney renal clear cell carcinoma.Scientific reports · 2025Article
- Mechanisms underlying hepatocellular carcinoma progression through N6-methyladenosine modifications of long non-coding RNA.World journal of gastroenterology · 2025Article
- Expressions of shox2, RASSF1A and PTGER4, and the relationship between their methylation and clinicopathological characteristics in patients with lung cancer.Journal of medical biochemistry · 2025Article
- Catching cancer signals in the blood: Innovative pathways for early esophageal cancer diagnosis.World journal of gastroenterology · 2025Article
- RFX2 downregulates RASSF1 expression and YAP phosphorylation through Hippo signaling to promote immune escape in lung adenocarcinoma.Cell division · 2025Article
- Epigenetic modifications in early stage lung cancer: pathogenesis, biomarkers, and early diagnosis.MedComm · 2025Review
- Diagnostic and prognostic value of polygene methylation detection in ascites.Frontiers in genetics · 2025Article
- The advances of DNA methylation in the liquid biopsy for the detection of lung cancer.Frontiers in oncology · 2025Review
- Anthracosis, epidemiology, gene and cancer: An updated mini-review.Caspian journal of internal medicine · 2025Review
- MTPC integration for improved diagnosis of pleural effusion.Frontiers in oncology · 2025Article
- Application of circulating tumor DNA methylation characteristics in early diagnosis and prognosis monitoring of lung cancer.American journal of translational research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundAn increasing number of studies have focused on the early diagnostic value of the methylation of RASSF1A and SHOX2 in lung cancer. However, the intricate cellular events related to RASSF1A and SHOX2 in lung cancer are still a mystery. For researchers and clinicians aiming to more profoundly understand the diagnostic value of methylated RASSF1A and SHOX2 in lung cancer, this review will provide deeper insights into the molecular events of RASSF1A and SHOX2 in lung cancer. METHODOLOGY: We searched for relevant publications in the PubMed and Google Scholar databases using the keywords "RASSF1A", "SHOX2" and "lung cancer" etc. First, we reviewed the RASSF1A and SHOX2 genes, from their family structures to the functions of their basic structural domains. Then we mainly focused on the roles of RASSF1A and SHOX2 in lung cancer, especially on their molecular events in recent decades. Finally, we compared the value of measuring RASSF1A and SHOX2 gene methylation with that of the common methods for the diagnosis of lung cancer patients.
resultsThe RASSF1A and SHOX2 genes were confirmed to be regulators or effectors of multiple cancer signaling pathways, driving tumorigenesis and lung cancer progression. The detection of RASSF1A and SHOX2 gene methylation has higher sensitivity and specificity than other commonly used methods for diagnosing lung cancer, especially in the early stage.
conclusionsThe RASSF1A and SHOX2 genes are critical for the processes of tumorigenesis, development, metastasis, drug resistance, and recurrence in lung cancer. The combined detection of RASSF1A and SHOX2 gene methylation was identified as an excellent method for the screening and surveillance of lung cancer that exhibits high sensitivity and specificity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.